Deutsche Labs Inc. Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Deutsche Labs Inc. Pharmaceutical Export Portfolio Dataset — 3 Products, $436.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Deutsche Labs Inc. — Pharmaceutical Exporter Profile (2026) | 3 Products, $436.9K Trade | TransData Nexus

Deutsche Labs Inc.

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $436.9K Total Trade · DGFT Verified

Deutsche Labs Inc. is an Indian pharmaceutical exporter with a total trade value of $436.9K across 3 products in 3 therapeutic categories. Based on 15 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Rifampicin ($240.9K), Pyrazinamide ($150.0K), Mefloquine ($46.0K).

Deutsche Labs Inc. — Export Portfolio & Destination Treemap

Deutsche Labs Inc. pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Deutsche Labs Inc.? — Company Overview & Market Position

Deutsche Labs Inc. is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered at 304 Sammani 11, Opposite Shell Petrol Pump, Satellite, Ahmedabad, Gujarat, India. The Corporate Identification Number (CIN) for Deutsche Labs Inc. is 26IN0805006362. (en.nbd.ltd) While specific revenue figures are not publicly disclosed, the company has demonstrated a consistent export performance, with a total export value of $437,000 USD across 15 shipments from 2022 to 2026. The workforce comprises approximately 20 employees, reflecting a focused operational structure. The company's official website is not publicly available.

What Does Deutsche Labs Inc. Export? — Product Portfolio Analysis

Top Products by Export Value

1Rifampicin$240.9K 2Pyrazinamide$150.0K

Product Portfolio — Top 3 by Export Value

Deutsche Labs Inc. exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Rifampicin	Advanced Antibiotics	$240.9K	6	0.0%	14
2	Pyrazinamide	Tuberculosis Medications	$150.0K	3	0.0%	12
3	Mefloquine	Antimalarial & Antiparasitic	$46.0K	6	1.9%	5

Deutsche Labs Inc. exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $436.9K. The top category is Advanced Antibiotics (55.1% of portfolio), followed by Tuberculosis Medications (34.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Deutsche Labs Inc. — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Deutsche Labs Inc. operates manufacturing facilities in Ahmedabad, Gujarat, India. Specific details regarding plant capacities and specializations are not publicly disclosed. The company's export data indicates a focus on finished pharmaceutical formulations, suggesting that its manufacturing facilities are equipped to produce a range of dosage forms, including tablets, capsules, syrups, and injections. However, without publicly available information, a detailed assessment of manufacturing capacities and specializations cannot be provided.

3Key Leadership

The key leadership of Deutsche Labs Inc. includes Michael Robinson, who serves as the President and Chief Executive Officer (CEO). Specific information regarding other executive roles, such as Chief Financial Officer (CFO) or Chief Operating Officer (COO), is not publicly available. The company's leadership appears to be centralized, with a focus on strategic decision-making at the top level.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Deutsche Labs Inc. Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Deutsche Labs Inc. has engaged in export activities to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates shipments to destinations such as the United States, with records of shipments arriving at ports like New York/Newark Area, Newark, New Jersey. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed. The absence of publicly available information on regulatory approvals suggests that Deutsche Labs Inc. may not have established formal market access in these regulated markets.

2Emerging Markets

Deutsche Labs Inc. has demonstrated export activities to emerging markets, including regions in Africa, Latin America, and Southeast Asia. For instance, the company has engaged in shipments to countries such as Guinea and Venezuela. While these activities indicate a presence in emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available. The lack of publicly disclosed information on such certifications suggests that Deutsche Labs Inc. may not possess WHO prequalification or similar certifications for its products.

3Geographic Strategy

Deutsche Labs Inc. — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Deutsche Labs Inc.'s FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The absence of such information suggests that the company may not have established formal approvals or registrations with the U.S. Food and Drug Administration (FDA). This lack of FDA approvals could limit the company's ability to market its products in the United States.

2WHO & EU GMP

There is no publicly available information indicating that Deutsche Labs Inc. holds World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. The absence of such certifications suggests that the company may not have undergone the necessary evaluations to meet these international standards. This lack of certification could affect the company's ability to access certain international markets that require such approvals.

3CDSCO & Indian Regulatory

Deutsche Labs Inc. — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Deutsche Labs Inc. operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors are not publicly identified, the company's export data indicates engagement with various international buyers, including those in the United States, Europe, and Africa. The lack of publicly available information on regulatory approvals and certifications may place the company at a competitive disadvantage compared to peers with established market access and recognized quality standards.

2Key Differentiators

Deutsche Labs Inc. specializes in finished pharmaceutical formulations, offering a range of dosage forms such as tablets, capsules, syrups, and injections. The company's export data indicates a focus on specific therapeutic categories, including advanced antibiotics, tuberculosis medications, and antimalarial & antiparasitic drugs. However, the absence of publicly available information on regulatory approvals and certifications suggests that the company may face challenges in differentiating itself in markets that require such credentials.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Deutsche Labs Inc. as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Deutsche Labs Inc. has demonstrated a consistent export performance, with a total export value of $437,000 USD across 15 shipments from 2022 to 2026. The company's export data indicates shipments to various international buyers, including those in the United States, Europe, and Africa. However, the absence of publicly available information on regulatory approvals and certifications suggests that the company may face challenges in establishing itself as a reliable supplier in markets that require such credentials.

2Certifications to Verify

Importers should verify the following certifications when considering Deutsche Labs Inc. as a supplier:

FDA Facility Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration.

WHO Prequalification: Ensure that products meet the World Health Organization's prequalification standards.

Frequently Asked Questions — Deutsche Labs Inc.

How many pharmaceutical products does Deutsche Labs Inc. export from India?

Deutsche Labs Inc. exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Rifampicin ($240.9K), Pyrazinamide ($150.0K), Mefloquine ($46.0K). Total export value is $436.9K.

What is Deutsche Labs Inc.'s total pharmaceutical export value?

Deutsche Labs Inc.'s total pharmaceutical export value is $436.9K, based on 15 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Deutsche Labs Inc. cover?

Deutsche Labs Inc. exports across 3 therapeutic categories. The largest are Advanced Antibiotics (55.1%, 1 products), Tuberculosis Medications (34.3%, 1 products), Antimalarial & Antiparasitic (10.5%, 1 products).

Get Full Deutsche Labs Inc. Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.